The present invention relates to novel heterocyclic compounds of general formula (I) their tautomers, stereoisomers, enantiomers, pharmaceutically acceptable salts and pharmaceutical composition. The compounds of general formula (I) belongs to the family of NOD like receptor family (NLR) protein NLRP3 modulators. Th...

The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparati...

The present invention relates to Fc variant protein and preparation thereof. Said Fc variant has altered binding affinity towards FcRn. Fc variant prepared according to the current invention can be used for making FcRn antagonist composition or can be used for making an Fc variant containing drug or molecule with al...

The present invention relates to novel compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions ...

Present invention describes synergistic composition comprising compound of formula (I) and at least one additional therapeutic agents such as ezetimibe, eicosapentaenoic acid, nicotinic acid derivatives and bempedoic acid derivatives, salt thereof. Invention also describes use of synergistic composition for the trea...

The current invention provides a DNA construct comprising S gene or S1 gene region of 2019-nCoV spike-S protein. The DNA construct of the present invention comprises DNA plasmid vector carrying S gene or S1 gene region of 2019-nCoV spike-S protein. The vector may further comprise a gene encoding IgE signal peptide o...

The present invention provides an antibody or antigen-binding portion thereof that can bind to properdin (factor P). The antibody of the current invention leads to selective inhibition of alternative complement pathway while allowing the classical and lectin pathways to continue. Further, the antibody of the present...

Present invention relates to development of prolyl hydroxylase inhibitor for treatment of Psoriasis and skin inflammatory diseases. Specifically, invention relates to development of compound of formula (Ia) for treatment of Psoriasis and skin inflammatory diseases. Invention also relates to pharmaceutical compositio...

The present invention relates to novel pharmaceutically acceptable salts of formula (Ia). The invention is also related to process for the preparation of the said novel salts and pharmaceutical composition of the same. Compounds of the present invention are prolyl hydroxylase inhibitors and are suitable for the trea...

The present invention relates to novel heterocyclic compounds of general formula (I) and their pharmaceutically acceptable salts, enantiomers and their diastereomers that are autotaxin (ATX) inhibitors. Compounds of general formula (I), their pharmaceutically acceptable salts and pharmaceutical composition are usefu...

The present invention generally relates to a pharmaceutical composition of suitable HIF prolyl hydroxylase inhibitors. Preferably, the present invention discloses novel formulations of the compound of formula (Ia), or pharmaceutically acceptable salts of compounds of formula (Ia). More particularly the present inven...

The present invention relates to an antibody or antigen-binding portion thereof that can bind to human programmed death 1 (PD-1). The antibody according to the present invention is further used in the preparation of a drug for treating disease in which expression of PD-1 is detrimental.

ABSTRACT “IMPROVED PROCESS FOR THE PREPARATION OF (R)-1-(TERT-BUTOXYCARBONYL)-2-METHYLPYRROLIDINE-2-CARBOXYLIC ACID” Present invention provides an improved process for the preparation of (R)-1-(tert-butoxycarbonyl)-2-methylpyrrolidine-2-carboxylic acid of formula (I).

ABSTRACT “Improved process for the preparation of Nirmatrelvir” Present invention relates to an improved process for the preparation of Nirmatrelvir. The present invention also relates to a novel amorphous form of the Nirmatrelvir and process for the preparation thereof. The invention also relates to pharmaceuti...

Present invention relates to development of compound of formula (Ia) for treatment of inflammatory bowel diseases. Invention also relates to pharmaceutical composition comprising therapeutically effective compound of formula (Ia) for treatment of inflammatory bowel diseases.

ABSTRACT "NOVEL NLRP3 INFLAMMASOME INHIBITORS" The present invention relates to novel compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, deuterated analogs, metabolites, diastereomers and polymorphs. The compounds are novel NLRP3 modu...

"Peptide(s) with protease activity and its use for the treatment or prevention of coronavirus infection" Abstract The present invention provides a composition comprising peptide(s) with protease activity. The composition according to the present invention is used for pharmaceutical purpose. It can also be used...

ABSTRACT “NOVEL POLYMORPHIC FORMS OF QUINOLONE BASED COMPOUNDS” The present invention relates to novel crystalline forms of quinolone based compounds and process for the preparation thereof, use thereof and pharmaceutical composition comprising the same.

ABSTRACT PROCESS FOR THE PREPARATION OF VOXELOTOR The present invention relates to a process for preparation of Voxelotor of Formula (I). The present invention also relates to a process for preparing intermediate useful in the preparation of Voxelotor. ...

A pharmaceutical formulation of anti-interleukin-5 antibody and preparation thereof Abstract The present invention provides a pharmaceutical formulation of anti-interleukin-5 (anti-IL-5) antibody, preferably mepolizumab. In one aspect, the pharmaceutical formulation of the present invention comprises therapeut...

ABSTRACT PROCESS FOR THE PREPARATION OF VILOXAZINE HYDROCHLORIDE The present invention relates to a process for preparation of Viloxazine hydrochloride. The present invention also relates to a process for preparing intermediates useful in the preparation of viloxazine hydrochloride.

ABSTRACT IMPROVED PROCESS FOR THE PREPARATION OF HIGHLY PURE RELUGOLIX The present invention relates to an improved process for the preparation of Relugolix, compound of Formula (I), substantially free from impurities. In particular, the invention relates to an improved process for the preparation of high purity ...

ABSTRACT “STABLE PHARMACEUTICAL COMPOSITIONS OF CALCIUM POLYSTYRENE SULFONATE” The present invention relates to provide a stable oral suspension of calcium polystyrene sulfonate. Further, present invention is also provides a process of preparation of a stable oral suspension of calcium polystyrene sulfonate. A sta...

ABSTRACT A pharmaceutical formulation of daratumumab antibody with suitable excipients The present invention provides a pharmaceutical formulation of daratumumab antibody with suitable pharmaceutical excipient(s). In one aspect, the pharmaceutical formulation of the present invention comprises therapeutically effe...

Present invention relates to development of compound of formula (I) for treatment of Cryopyrin Associated Periodic Syndromes (CAPS). Specifically, the present invention provides a NLRP3 inhibitors or its pharmaceutically acceptable salt for treatment of Cryopyrin Associated Periodic Syndromes (CAPS). Invention also ...

Present invention relates to combination of Apremilast or pharmaceutically acceptable salts thereof and Rifaximin or its polymorphs or isomers or pharmaceutically acceptable salts. Present invention provides the pharmaceutical composition of Apremilast or pharmaceutically acceptable salts thereof and Rifaximin or it...

ABSTRACT “PROCESS FOR THE PREPARATION OF QUINOLONE BASED COMPOUNDS” The present invention relates to an improved process for the preparation of quinolone based compounds of general formula (I) using intermediate compound of general formula (XII). Invention also provides an improved process for the preparation ...

This invention relates to a field of pharmaceuticals, in particular to desidustat particles having specific particle size distribution and pharmaceutical compositions thereof.

ABSTRACT A PROCESS FOR PREPARATION OF TRIAMINOPYRIMIDINE COMPOUND AND INTERMEDIATES THEREOF The present invention relates to crystalline triaminopyrimidine compound 1, or pharmaceutically acceptable salts thereof, or hydrates, or solvates, or polymorphs, or optically active forms thereof, in solid state forms. Th...

The present invention relates to pharmaceutical compositions of ozanimod or a pharmaceutically acceptable salt thereof. In particular, the invention relates to pharmaceutical compositions of ozanimod or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and optionally one...

The present invention relates to the development of therapeutic compound for the treatment of brain psychiatric diseases. Specifically, the present invention provides a NLRP3 inhibitors or its pharmaceutically acceptable salt or suitable composition useful in the treatment of neuroinflammatory disorders or neurodege...

The present invention provides a stable pharmaceutical composition comprising apomorphine and one or more pharmaceutically acceptable carriers in an injectable device. The present invention also provides a process for preparing the stable pharmaceutical composition.

The invention relates to an amorphous solid dispersion of a quinolone compound of Formula I and process for the preparation thereof.

ABSTRACT “PROCESS FOR OBTAINING PURE POLYMORPHIC FORMS OF QUINOLONE BASED COMPOUND” The present invention relates to a process for obtaining pure polymorphic form I of quinolone based compound of formula (I). The present invention also relates to process for obtaining pure polymorphic form II of formula (I). ...

IMPROVED PROCESS FOR THE PREPARATION OF SULFONYLUREA BASED COMPOUNDS ABSTRACT The present invention relates to an improved process for the preparation of sulfonylurea based compounds of general formula (I). More specifically present invention provides an improved process for the preparation of compound of formula...

ABSTRACT SOLID FORM OF CENTANAFADINE AND PROCESS FOR PREPARATION THEREOF The present invention relates to a crystalline form of centanafadine free base and eutectic mixture of centanafadine hydrochloride, compound of Formula I with co-former and process for preparation thereof. The present invention also relat...

The present invention provides a provides a pharmaceutical composition for inhalation comprising at least one long acting muscarinic antagonist, at least one long-acting ß-adrenoceptor agonist and one or more pharmaceutically acceptable excipients. The invention also provides the process of preparing pharmaceutical ...

ABSTRACT “IMPROVED PROCESS FOR THE PREPARATION OF 3-OXO-3,4-DIHYDRO-2H-BENZO[B][1,4]THIAZINE-6-CARBALDEHYDE” Present invention provides an improved process for the preparation of 3-Oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carbaldehyde. The present invention also provides novel intermediate and its use for the ...

ABSTRACT A PROCESS FOR THE PREPARATION OF DEUCRAVACITINIB AND A NOVEL INTERMEDIATE THEREOF The present invention relates to a process for the preparation of deucravacitinib, or a pharmaceutically acceptable salt, or a solvate thereof. Further, the present invention relates to a novel intermediate compound and proc...

Present invention relates to topical pharmaceutical composition of suitable HIF prolyl hydroxylase inhibitors. Preferably, present invention is about the topical pharmaceutical composition of compound of formula (Ia). Disclosed topical pharmaceutical composition comprises compound of formula (Ia) or its pharmaceutic...

ABSTRACT ANTHRAQUINONE DERIVATIVES TO TREAT CYTOKINE-RELATED DISORDERS The invention provides compounds of the general formula (I) having the potential to treat cytokine-related disorders especially osteoarthritis, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceut...

The present invention relates to compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions conta...

Present invention relates to development of compound of formula (Ia) for treatment of sickle cell anaemia. Invention also relates to the pharmaceutical composition comprising compound of formula (Ia) or its pharmaceutically acceptable salts for treatment of sickle cell anaemia.

The present invention relates to novel crystalline forms of a quinolone compound of Formula (I). The invention also relates to processes for the preparation crystalline forms of the compound of Formula (I). Further the disclosure provides a process for the preparation of compound of Formula (I), intermediates, impur...

ABSTRACT A GREEN PROCESS FOR THE PREPARATION OF CRYSTALLINE DESIDUSTAT The present invention relates to a field of pharmaceuticals, in particular to an improved process for the preparation of a crystalline form of desidustat substantially free from other crystalline forms. The process can provide the crystalline...

ABSTRACT IMPROVED PROCESS FOR THE PREPARATION OF SITAGLIPTIN FREE FROM GENOTOXIC IMPURITIES The present invention relates to sitagliptin or a pharmaceutically acceptable salt thereof substantially free from genotoxic impurities particularly nitrosamine impurities and processes for its preparation. In particular...

Process of purifying anti-CD38 antibody Abstract The present invention provides process of purification of anti-CD38 antibody, preferably, daratumumab comprises affinity chromatography followed by cation exchange chromatography followed by mixed mode chromatography. Aspects of the present invention further compr...

The invention relates to once a day pharmaceutical compositions comprising a fixed dose combination of a ?? blocker or a pharmaceutically acceptable salt or ester thereof and an SGLT2 inhibitor or a pharmaceutically acceptable salt or ester thereof with one or more pharmaceutically acceptable excipients. In addition...

The present invention relates to the development of therapeutic compound for the treatment of glomerular diseases. Specifically, present invention relates to use of compound of formula (Ia) or its pharmaceutically acceptable salt or combination thereof or pharmaceutical composition thereof for the treatment of glome...

The present invention relates to novel compounds of general formula (1), their suitable pharmaceutically acceptable salts, their solvates, their hydrates, their stereoisomers, their polymorphs, their racemic mixtures, their optically active forms and their use in the treatment of inflammatory conditions such as psor...

ABSTRCT “NEW PROCESS FOR PREPARATION OF AFICAMTEN” The present invention relates to a new process for preparation of Aficamten. The present invention also relates to a novel intermediate compound or a salt, isomer or mixture thereof. Further, the present invention relates to a process for preparation of novel in...

A combination of vaccine formulation against human papillomavirus and hepatitis E virus infection Abstract Present invention provides a vaccine formulation comprising of human papillomavirus (HPV) virus like particles (VLPs) in combination with hepatitis E virus antigen (HEV) and suitable excipients. Preferred h...

ABSTRACT AMORPHOUS FORM OF RESMETIROM AND PROCESS FOR PREPARATION THEREOF The present invention relates to an amorphous form of resmetirom. In particular, the present invention relates to an amorphous solid dispersion of resmetirom. The present invention relates to processes for the preparation of amorphous form...

ABSTRACT A PROCESS FOR THE PREPARATION OF A CRYSTALLINE FORM OF DEUCRAVACITINIB The present invention relates to an improved process for the preparation of a crystalline form of deucravacitinib. The process provides the crystalline form of deucravacitinib on consistent basis with a high purity and substantially fr...

ABSTRACT COMPOSITION COMPRISING HIGH PURITY DEUCRAVACITINIB AND METHOD FOR PREPARATION THEREOF The present invention relates to high purity deucravacitinib, compositions and process for the preparation thereof. In particular, the present invention relates to compositions comprising deucravacitinib having a purit...

ABSTRACT ORAL MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS OF AZATHIOPRINE The present invention relates to oral modified release pharmaceutical compositions of azathioprine comprising plurality of delayed release azathioprine particles, and at least one pharmaceutically acceptable excipient. Further, the modifi...

ABSTRACT PROCESSES FOR THE PREPARATION OF MIRABEGRON FREE FROM GENOTOXIC IMPURITIES The present invention relates to mirabegron substantially free from genotoxic impurities particularly nitrosamine impurities of Formula (I), (II), (III), (IV), (V) and processes for its preparation. In particular, the invention r...

ABSTRACT “AN IMPROVED PROCESS FOR THE PREPARATION OF A CRYSTALLINE FORM OF A TRIAMINOPYRIMIDINE COMPOUND” The present invention relates to a field of pharmaceuticals, in particular to an improved process for the preparation of a crystalline form of triaminopyrimidine compound of Formula I as described herein. ...

The invention provides compounds which are active to control IL17A mediated pathways and their use for the treatment of inflammatory diseases. The novel compounds are defined by the general formula (1) as given below. The compounds of the present invention are useful in the treatment of the human or animal body. The...

The aim of the invention is to provide liquid composition of Semaglutide with phenol in concentration of 0.11% w/w to 0.5% w/w which will enhance stability of the composition. Also provided herein a process for the preparation of composition of Semaglutide and method of using the same for treating diabetes and obesi...

The present invention relates to lyophilized pharmaceutical compositions of copper histidinate and one or more pharmaceutically acceptable excipients. It also relates to processes for preparing such compositions.

The present invention describes a combination of a suitable prolyl hydroxylase inhibitors with a suitable thrombopoietin (TPO) receptor agonist for the treatment of Aplastic anemia (AA). The invention also describes the preparation of such combination and its compositions.

The present invention provides novel compounds of Formula (I) or its pharmaceutically acceptable salts. The novel compounds reported in present invention are suitable for the treatment against infection caused by Gram-positive bacteria.

The present invention relates to an improved process for the preparation of sulfonylurea based compounds of general formula (I). More specifically present invention provides an improved process for the preparation of compound of formula (I-a). Present invention also provides some novel impurities generated during pr...

ABSTRACT A PROCESS FOR THE PREPARATION OF A TRIAMINOPYRIMIDINE COMPOUND AND NOVEL INTERMEDIATES THEREOF The present invention relates to a process for the preparation of a triaminopyrimidine compound of Formula I. Further, the present invention relates to the novel intermediate compounds and process for preparat...

The present invention describes a combination of clobetasol and hyaluronate with an average molecular weight of between 40 and 60 kDa for the treatment of Psoriasis. The formulation is preferably in a topical form. The topical pharmaceutical composition comprises, a therapeutically effective amount of 0.01 to 0.05% ...

The present invention relates to FcRn-antagonist or Fc variant(s) protein and preparation thereof. Said Fc variant(s) has altered binding affinity towards FcRn. In one aspect, the Fc variant(s) according to the present invention comprises L234A, L235A, T307N, V308P, L309Y, P329G, H433R, N434W amino acid substitution...

The present invention provides novel stable pharmaceutical formulation of anti-HER2 antibody, preferably pertuzumab formulated in presence of arginine containing buffer(s), wherein the arginine containing buffer is selected from arginine-succinate buffer, arginine-phosphate buffer arginine-acetate buffer, arginine-a...

ABSTRACT PROCESS FOR THE PREPARATION OF DARUNAVIR A process for the preparation of darunavir comprises the reacting of 4-amino-N-(2R,3S) (3-amino-2-hydroxy-4-phenylbutyl)-N-isobutyl-benzenesulfonamide with 2,5-dioxopyrrolidin-1-yl((3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl) carbonate in N,N-dimethyl formamide (...

ABSTRACT A PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR THE PREPARATION OF A TRIAMINOPYRIMIDINE COMPOUND The present invention relates to a process for the preparation of intermediates for the preparation of a triaminopyrimidine compound. Particularly, the invention relates to an improved process for the pr...

The present invention provides method of preparing brentuximab vedotin with purity of more than 97 % comprising reduction and conjugation of brentuximab with mc-vc-PABC-MMAE in a suitable buffer and at a suitable pH in which brentuximab antibody was kept. The present invention provides method of purifying brentuxi...

The invention provides antibody linker drug conjugates wherein antibody is sacituzumab and drug is auristatin analogues or a pharmaceutically acceptable salt thereof. The invention also provides a process of preparing antibody linker conjugates of the present invention.

The invention provides antibody linker drug conjugates wherein antibody is daratumumab and drug is auristatin analogues or a pharmaceutically acceptable salt thereof. The invention also provides a process of preparing antibody linker conjugates of the present invention.